Stockscreener 앱 받기
5.88
7.55%
-0.48
시간 외 거래:
5.77
-0.11
-1.87%
전일 마감가:
$6.36
열려 있는:
$6.21
하루 거래량:
151.30K
Relative Volume:
1.49
시가총액:
$149.69M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-4.1702
EPS:
-1.41
순현금흐름:
$-15.54M
1주 성능:
-8.55%
1개월 성능:
-2.08%
6개월 성능:
-36.43%
1년 성능:
-6.81%
1일 변동 폭
$5.80
$6.21
1주일 범위
$5.80
$7.00
52주 변동 폭
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
5.88 | 161.91M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Maxim Group | Buy |
| 2025-03-17 | 개시 | Laidlaw | Buy |
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Nuvectis Pharma Grows Its Cash Pile While Chasing Cancer Trials - Finimize
Nuvectis Pharma Doubles Down On R&D Despite Rising Losses - Finimize
Will Rising Costs Hurt Lancor Holdings Limited’s Margins This YearCurrency Fluctuation Impact & Free High Frequency Trading Ideas - earlytimes.in
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Nuvectis Pharma Q3 net loss widens on milestone expenses - MarketScreener
Nuvectis Pharma (NASDAQ: NVCT) posts third quarter results: $7.5M net loss; runway to 3Q-2027 - Stock Titan
Nuvectis Pharma, Inc. SEC 10-Q Report - TradingView
Nuvectis Pharma reveals Q3 2025 financial performance and strategic business updates - Traders Union
Nuvectis Pharma (NASDAQ: NVCT) initiates NXP900 Phase 1b; cash at $35.4M in Q3 results - Stock Titan
What makes Nuvectis Pharma Inc. stock attractive to growth fundsJuly 2025 Setups & Detailed Earnings Play Alerts - newser.com
Does Nuvectis Pharma Inc. qualify in momentum factor screeningMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.Sell Signal & Technical Pattern Recognition Alerts - newser.com
What data driven models say about Nuvectis Pharma Inc.’s futureMarket Trend Summary & Fast Gain Swing Alerts - newser.com
Is Nuvectis Pharma Inc a good long term investmentStock Split Announcements & High Yield Market Growth - earlytimes.in
Why Nuvectis Pharma Inc. stock remains undervaluedEarnings Summary Report & Fast Moving Trade Plans - newser.com
Nuvectis Pharma Inc. stock trendline breakdownJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
How strong is Nuvectis Pharma Inc. stock revenue growthJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cyclesJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averagesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Nuvectis Pharma Shares: Poised for Significant Growth? - AD HOC NEWS
Nuvectis Pharma : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Acquires 46,900 Shares of Stock - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Purchases $215,459.10 in Stock - MarketBeat
A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st
What's Driving Renewed Interest In Nuvectis Pharma's Oncology Strategy? - RTTNews
Major Investment Alert: Insider Buys Big in Nuvectis Pharma! - TipRanks
Insider Stock Purchases: October 29, 2025 - Quiver Quantitative
Nuvectis Pharma Stock (NVCT) Opinions on NXP900 Trial Results - Quiver Quantitative
Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing - MarketScreener
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Can Nuvectis Pharma Inc. stock hit analyst price targetsMarket Volume Summary & Daily Technical Forecast Reports - fcp.pa.gov.br
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target By Investing.com - Investing.com South Africa
Can Nuvectis Pharma Inc. stock reach $100 price targetJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):